Celula China Med-Technology Co., Ltd. (hereinafter referred to as "Celula"), a company that mainly provides reproductive health, precision medicine and POCT clinical diagnostic equipment, has recently announced the completion of Series B financing of tens of millions of RMB, which will be used mainly for the registration application and marketing of POCT flow cytometer and reproductive health-related test kit.

It is learned that this series of financing was led by Hanne Capital, followed by old shareholders Kinghall Ventures, CD Capital, and CELULA-HK (including VERSANT VENTURES, KAISER PERMANENTE VENTURES, and other well-known U.S. investment institutions and several angel investors).

Celula has so far raised over RMB 200 million in China. 

Source: iyiou.com

Celula is a company with advanced gene detection technologies, focusing on the area of reproductive health, with technologies and products under it including two new NIPT technologies, ASSURIT and ASSUREDX, a new-generation flow cytometer, SPARROW, and various self-developed test kits.

The founder Dr. Zhang Haichuan obtained a doctorate in Precision Instruments and Mechanology from Tsinghua University in 1997. He owns over 50 patents and has led the establishment of various core technologies, e.g. non-invasive prenatal and flow cytometer.

Technologies and Patents of the Company

In 2013, Celula established its headquarters in Chengdu, Sichuan, China, and business offices in Beijing, Shanghai, and Hengqin, Zhuhai. At present, it has established a complete scientific research, technical transformation, production and service base of over 5,000 square meters.

The Company now has R&D, production and sales management teams with nearly 100 members and has established close cooperation with many well-known enterprises and famous experts in China and abroad. It has over 20 domestic and foreign patents and many quality products in China that have obtained the qualifications of the NMPA.

New-Generation Small SPARROW Flow Cytometer

Among them, the new-generation small SPARROW flow cytometer independently developed by Celula received the Registration Certificate for Medical Device approved by the NMPA in 2019, which is the first self-branded small flow cytometer product approved for marketing in China. (Click here to view details)

Company address: B1-902, Tianfu Life Science Park, No. 88, Keyuan South Road, Chengdu Hi-Tech Industrial Development Zone, Chengdu, Sichuan

More news:

• Celula: Making Affordable and Convenient Chinese Gene Detection Products Available to the Public

• Celula's 8 Sperm Flow Cytometry Reagents for Male Infertility Approved for Marketing

Source: iyiou.com